Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV

Nicola Squillace, Alessandro Soria, Giorgio Bozzi, Andrea Gori, Alessandra Bandera

Research output: Contribution to journalReview article

Abstract

Introduction: The burden of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is increasing worldwide. This phenomenon poses a potentially dangerous risk of rise in mortalities caused by cirrhosis and liver cancer. Owing to a complex combination of factors, NAFLD and NASH arise in a majority of people living with HIV (PLWH), but accurate estimates of prevalence differ, depending on sample selection, type of analysis, and data interpretation. The wide range of diagnostic tools used to assess liver steatosis and lack of control groups in many studies further contributes to current difficulties in properly assessing prevalence of these conditions. Areas covered: Thoroughly scrutinizing the current literature, we compared the prevalence of NAFLD and NASH in PLWH to rates found in the general population. We highlighted strengths and limitations of the studies, in order to determine the effective impact of these medical conditions in PLWH. Expert opinion: The prevalence and progression of NAFLD in human immunodeficiency virus (HIV) infection are reported to be widely variable. HIV infection itself and antiretroviral treatment have been demonstrated to play a role in the development of NAFLD. Larger and more effective studies are needed to evaluate the effects of NASH in PLWH and its progression.

Original languageEnglish
Pages (from-to)643-650
Number of pages8
JournalExpert Review of Gastroenterology and Hepatology
Volume13
Issue number7
DOIs
Publication statusPublished - Jul 3 2019

Fingerprint

Fatty Liver
HIV
Virus Diseases
Non-alcoholic Fatty Liver Disease
Expert Testimony
Liver Neoplasms
Fibrosis
Control Groups
Mortality

Keywords

  • Antiretroviral therapy
  • hepatic steatosis
  • HIV
  • nonalcoholic fatty liver disease
  • nonalcoholic steatohepatitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV. / Squillace, Nicola; Soria, Alessandro; Bozzi, Giorgio; Gori, Andrea; Bandera, Alessandra.

In: Expert Review of Gastroenterology and Hepatology, Vol. 13, No. 7, 03.07.2019, p. 643-650.

Research output: Contribution to journalReview article

Squillace, Nicola ; Soria, Alessandro ; Bozzi, Giorgio ; Gori, Andrea ; Bandera, Alessandra. / Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV. In: Expert Review of Gastroenterology and Hepatology. 2019 ; Vol. 13, No. 7. pp. 643-650.
@article{0086af88e05f4350927d8f1405751f4a,
title = "Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV",
abstract = "Introduction: The burden of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is increasing worldwide. This phenomenon poses a potentially dangerous risk of rise in mortalities caused by cirrhosis and liver cancer. Owing to a complex combination of factors, NAFLD and NASH arise in a majority of people living with HIV (PLWH), but accurate estimates of prevalence differ, depending on sample selection, type of analysis, and data interpretation. The wide range of diagnostic tools used to assess liver steatosis and lack of control groups in many studies further contributes to current difficulties in properly assessing prevalence of these conditions. Areas covered: Thoroughly scrutinizing the current literature, we compared the prevalence of NAFLD and NASH in PLWH to rates found in the general population. We highlighted strengths and limitations of the studies, in order to determine the effective impact of these medical conditions in PLWH. Expert opinion: The prevalence and progression of NAFLD in human immunodeficiency virus (HIV) infection are reported to be widely variable. HIV infection itself and antiretroviral treatment have been demonstrated to play a role in the development of NAFLD. Larger and more effective studies are needed to evaluate the effects of NASH in PLWH and its progression.",
keywords = "Antiretroviral therapy, hepatic steatosis, HIV, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis",
author = "Nicola Squillace and Alessandro Soria and Giorgio Bozzi and Andrea Gori and Alessandra Bandera",
year = "2019",
month = "7",
day = "3",
doi = "10.1080/17474124.2019.1614913",
language = "English",
volume = "13",
pages = "643--650",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV

AU - Squillace, Nicola

AU - Soria, Alessandro

AU - Bozzi, Giorgio

AU - Gori, Andrea

AU - Bandera, Alessandra

PY - 2019/7/3

Y1 - 2019/7/3

N2 - Introduction: The burden of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is increasing worldwide. This phenomenon poses a potentially dangerous risk of rise in mortalities caused by cirrhosis and liver cancer. Owing to a complex combination of factors, NAFLD and NASH arise in a majority of people living with HIV (PLWH), but accurate estimates of prevalence differ, depending on sample selection, type of analysis, and data interpretation. The wide range of diagnostic tools used to assess liver steatosis and lack of control groups in many studies further contributes to current difficulties in properly assessing prevalence of these conditions. Areas covered: Thoroughly scrutinizing the current literature, we compared the prevalence of NAFLD and NASH in PLWH to rates found in the general population. We highlighted strengths and limitations of the studies, in order to determine the effective impact of these medical conditions in PLWH. Expert opinion: The prevalence and progression of NAFLD in human immunodeficiency virus (HIV) infection are reported to be widely variable. HIV infection itself and antiretroviral treatment have been demonstrated to play a role in the development of NAFLD. Larger and more effective studies are needed to evaluate the effects of NASH in PLWH and its progression.

AB - Introduction: The burden of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is increasing worldwide. This phenomenon poses a potentially dangerous risk of rise in mortalities caused by cirrhosis and liver cancer. Owing to a complex combination of factors, NAFLD and NASH arise in a majority of people living with HIV (PLWH), but accurate estimates of prevalence differ, depending on sample selection, type of analysis, and data interpretation. The wide range of diagnostic tools used to assess liver steatosis and lack of control groups in many studies further contributes to current difficulties in properly assessing prevalence of these conditions. Areas covered: Thoroughly scrutinizing the current literature, we compared the prevalence of NAFLD and NASH in PLWH to rates found in the general population. We highlighted strengths and limitations of the studies, in order to determine the effective impact of these medical conditions in PLWH. Expert opinion: The prevalence and progression of NAFLD in human immunodeficiency virus (HIV) infection are reported to be widely variable. HIV infection itself and antiretroviral treatment have been demonstrated to play a role in the development of NAFLD. Larger and more effective studies are needed to evaluate the effects of NASH in PLWH and its progression.

KW - Antiretroviral therapy

KW - hepatic steatosis

KW - HIV

KW - nonalcoholic fatty liver disease

KW - nonalcoholic steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=85067625430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067625430&partnerID=8YFLogxK

U2 - 10.1080/17474124.2019.1614913

DO - 10.1080/17474124.2019.1614913

M3 - Review article

C2 - 31081390

AN - SCOPUS:85067625430

VL - 13

SP - 643

EP - 650

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 7

ER -